Vanda Pharmaceuticals (VNDA) Sinks as Red Flags Raised
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Jefferies Boosts Price Target on Vanda (VNDA) to $11 Amid Sell-Off
June 20, 2013 1:53 PM EDTJefferies analyst Corey Davis reiterated a Buy rating and raised his price target on Vanda Pharmaceuticals (NASDAQ: VNDA) from $7 to $11 amid Wednesday's 22% sell-off on a negative article at TheStreet.
Davis notes, "VNDA's up >100% since our upgrade and despite new Tasi approvability fears we... More
Lazard Capital Defends Vanda (VNDA), Calls Reports 'Inflammatory'
June 19, 2013 1:56 PM EDTLazard Capital today maintained a Buy rating on Vanda Pharmaceuticals (NASDAQ: VNDA) with a price target of $19.00. The note follows negative comments in the Street.com, which led to a sharp sell-off.
Analyst Joshua Schimmer called comments a "surprisingly inflammatory assessment of tasimelteon's approval... More
Vanda (VNDA) Presents Data on Tasimelteon
June 19, 2013 7:29 AM EDTVanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) presented additional data today at ENDO 2013, the Endocrine Society's 95th Annual Meeting, demonstrating that tasimelteon can entrain (synchronize) both melatonin and cortisol rhythms. This effect further confirms tasimelteon's potential to reset the master body clock and address the circadian desynchrony which is inherent in Non-24-Hour Disorder (Non-24). The SET (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study of the Efficacy and Safety of Tasimelteon to treat Non-24-Hour Disorder) Phase III studies were designed to assess the safety, efficacy and maintenance effect of tasimelteon for... More
